Psychiatric University Hospital, Zurich psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Psychiatric University Hospital, Zurich is listed with 6 registered studies counted here, in Zurich, Switzerland. By compound: 1 psilocybin, 1 LSD, 2 DMT, 1 ayahuasca and 3 ketamine. By registry status: 2 recruiting and 4 completed. By phase: 3 early phase 1, 2 phase 2 and 1 not applicable. Reported start years run from 2015 (earliest) to 2025 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 6 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 1 |
| LSD | 1 |
| DMT | 2 |
| Ayahuasca | 1 |
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 33% |
| Completed | 4 | 67% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 3 | 50% |
| Phase 2 | 2 | 33% |
| Not applicable | 1 | 17% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder | NCT06969937 | Recruiting | Phase 2 | 2025-06-01 | Ketamine |
| Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction | NCT06125054 | Recruiting | Phase 2 | 2024-02-05 | Ketamine |
| Mindfulness and Psychedelics | NCT05780216 | Completed | Early Phase 1 | 2023-02-20 | Psilocybin, DMT, Ayahuasca |
| Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects | NCT04716335 | Completed | Early Phase 1 | 2020-12-01 | DMT |
| The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers | NCT02451072 | Completed | Not applicable | 2015-03-01 | LSD |
| A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine | NCT03609190 | Completed | Early Phase 1 | 2015-01-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | LSD | DMT | Ayahuasca | Ketamine